Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Grant
Overview
Affiliation
Overview
Awarded By
National Marrow Donor Program
Total Award Amount
593008.00
Direct Costs
456160.00
Sponsor Award Id
Affiliation
Contributor
Antonio Di Stasi M.D.
Principal Investigator
Donna Salzman M.D.
Investigator
Luciano Costa M.D., Ph.D.
Investigator
Racquel Innis-Shelton M.D.
Investigator
Ravi Bhatia M.D.
Investigator